查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015187

肠外营养市场：2026-2032年全球市场预测（依产品类型、成分、给药途径、给药方法、应用及最终用户划分）

Parenteral Nutrition Market by Product Type, Composition, Route Of Administration, Delivery Mode, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肠外营养市场价值将达到 81.6 亿美元，到 2026 年将成长至 85.7 亿美元，到 2032 年将达到 120.8 亿美元，复合年增长率为 5.74%。

主要市场统计数据
基准年 2025 81.6亿美元
预计年份：2026年 85.7亿美元
预测年份 2032 120.8亿美元
复合年增长率 (%) 5.74%

简明扼要地概述了肠外营养的当前趋势，并将其置于临床实践变革和行业战略挑战的背景下进行分析。

肠外营养在现代临床护理中发挥着至关重要的作用，它为无法耐受或利用经肠营养的患者提供营养。近年来，药物科学、配药技术和护理模式的进步，彻底改变了临床医生、药剂师和医疗保健系统在急性和慢性疾病治疗中应用肠外疗法的方式。因此，相关人员必须应对日益复杂的局面，这些局面涉及临床优先事项、安全规程和供应链韧性之间的相互作用。

技术突破、调节加强和医疗保健环境的演变如何共同重塑肠外营养输送、安全性和临床应用的范式。

肠外营养领域正经历一场变革，其驱动因素包括：临床需求、监管机构对无菌性和安全性的重视，以及配製和给药技术的进步。首先，对持续性照护的需求以及门诊和居家治疗的兴起，迫使生产者和医疗服务提供者重新调整产品系列，优先考虑产品的稳定性、给药便利性和与远端监测的兼容性。这一演变与日益重视以病人为中心的照护路径以及缩短住院时间的需求相契合。

评估新关税政策对肠外营养供应链和商业模式的多方面营运、采购和策略影响。

美国在2025年实施的新关税措施，为肠外营养产业的采购、生产决策和定价策略等各环节带来了独特的压力。对关键进口原料和成品征收的关税推高了依赖全球供应链的製造商和药房的收货成本，促使他们重新评估采购地点和供应商关係。为此，许多相关人员将加强对供应商合约的审查，在品质和监管合规的前提下优先考虑近岸外包，并加快供应商合格审核，以降低贸易波动带来的风险。

详细的細項分析揭示了产品类型、成分、护理环境、临床用途、剂型和给药途径如何决定不同的策略重点。

细分市场的趋势揭示了每种产品类型、成分、终端用户群体、应用、剂型和给药途径的不同机会和风险。在产品类型方面，週边静脉营养主要针对短期或强度较低的需求，与门诊和居家照护策略相契合；而全静脉营养针对需要全面营养支持的复杂临床病例，在住院患者的重症监护和肿瘤治疗中仍然占据核心地位。这些截然不同的特征影响着各医疗机构的需求模式、库存管理实务和配药要求。

临床实务、监管严格程度和生产能力的区域差异，决定了商业化和供应韧性的不同路径。

区域环境塑造了美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、监管环境和供应链结构，每个区域都对其商业性和营运产生独特的影响。在美洲，医疗保健系统内部急性护理网络和居家医疗提供者之间密切合作，这催生了对医院全肠外营养（TPN）解决方案和家庭週边给药方案的需求。法律规范强调药物警戒和无菌配製标准，而报销机制则越来越重视缩短住院时间和降低再入院率等结果，从而奖励支持安全门诊过渡的产品和服务组合。

竞争优势源自于成熟的无菌生产流程、产品易用性、供应链韧性以及塑造长期市场接受度的临床伙伴关係。

肠外营养领域的竞争格局主要围绕着配方科学、无菌生产、分销网络覆盖范围、临床合作能力。主要企业优先投资于检验的配药平台、完善的品质系统和封闭式系统技术，以最大限度地降低污染风险，并证明其符合不断发展的无菌操作标准。製造商与医疗系统或第三方配药服务商建立策略合作伙伴关係，已成为在维持临床监管的同时扩大分销规模的常用手段。

领导者可采取切实可行的策略步骤，以提高品质、实现供应链多元化、改善产品易用性并深化临床伙伴关係，以实现永续成长。

产业领导者应推动一系列连贯的倡议，以增强韧性、实现服务差异化，并使业务模式与不断变化的临床重点保持一致。首先，应优先投资于品质系统和检验的配药基础设施，以确保持续的无菌性和符合监管要求。这项基础性步骤将降低临床风险，并使机构能够在医院和门诊环境中扩展服务规模。其次，应促进供应链多元化，并选择性地将关键零件的生产外包到近岸地区，以降低关税风险并缩短前置作业时间。策略供应商伙伴关係和区域製造合作将有助于顺利过渡并维持医疗保健服务的连续性。

我们采用严谨的混合方法，结合专家访谈、政策审查和情境分析，得出了可操作的临床和商业性见解。

本次高阶主管分析所依据的研究采用了一种结构化的多面向调查方法，旨在全面了解肠外营养的临床、监管、商业性和营运等各个面向。主要研究包括对临床负责人、首席药剂师、配药专家和采购主管进行结构化访谈，以了解决策标准、挑战和推广应用的驱动因素。这些定性研究结果与监管文件、配药标准和已发表的临床文献进行了交叉比对，以确保其与当前的实践和安全预期相符。

一项前瞻性的综合分析强调了协调品质、供应弹性和临床伙伴关係关係的重要性，以确保在肠外营养领域保持长期领先地位。

总之，肠外营养兼具临床必要性与操作复杂性。该领域的未来发展将受到以下因素的共同影响：更安全的配药技术、无菌操作的监管要求、医疗服务模式向居家和门诊模式的转变，以及各机构应对价格波动带来的衝击的战略倡议。投资于品管系统、实现采购多元化并致力于提供以临床医生为中心的产品和服务的利益相关人员，将更有利于维持医疗服务的可及性并推动患者疗效的改善。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肠外营养市场：依产品类型划分

  • 周边静脉营养
  • 全静脉营养

第九章：肠外营养市场：依成分划分

  • 胺基酸溶液
  • 碳水化合物溶液
  • 电解质溶液
  • 脂质乳剂
  • 维生素和微量元素溶液

第十章：静脉营养市场：依给药途径划分

  • 中心静脉导管
  • 週边管路

第十一章：肠外营养市场：依给药途径划分

  • 风俗
    • 院内准备
    • 外部给药
  • 预混合料
    • 多腔袋
    • 单隔层包

第十二章：肠外营养市场：依应用领域划分

  • 重症监护
  • 肿瘤营养
  • 手术营养

第十三章 肠外营养市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院

第十四章 肠外营养市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肠外营养市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肠外营养市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肠外营养市场

第十八章：中国肠外营养市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Aculife Healthcare
  • Ajinomoto Co. Inc.
  • Amanta Healthcare
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Grifols SA
  • ICU Medical, Inc.
  • JW Pharmaceutical Corporation
  • Meiji Holdings Co., Ltd.
  • Option Care Health Inc.
  • Otsuka Pharmaceutical Co.
  • Pfizer Inc.
  • Sichuan Kelun Pharmaceutical Co., Ltd.
Product Code: MRR-036C5CF3B549

The Parenteral Nutrition Market was valued at USD 8.16 billion in 2025 and is projected to grow to USD 8.57 billion in 2026, with a CAGR of 5.74%, reaching USD 12.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.16 billion
Estimated Year [2026] USD 8.57 billion
Forecast Year [2032] USD 12.08 billion
CAGR (%) 5.74%

A concise orienting overview that situates current parenteral nutrition developments within clinical practice transformation and strategic industry imperatives

Parenteral nutrition occupies an essential role in modern clinical care by providing intravenous nourishment to patients who cannot tolerate or access enteral feeding. Over recent years, advances in formulation science, compounding technologies, and care delivery models have reshaped how clinicians, pharmacists, and health systems employ parenteral therapies across acute and chronic settings. Consequently, stakeholders must navigate an increasingly complex landscape where clinical priorities, safety protocols, and supply-chain resilience intersect.

This executive summary synthesizes the prevailing dynamics that influence parenteral nutrition, emphasizing technological innovation, regulatory evolution, and shifts in care settings. It draws attention to the operational challenges providers confront-ranging from compounding compliance to aseptic processing-and highlights how industry participants are adapting through new product configurations and service models. By framing core trends and implications, this introduction sets the stage for deeper analysis of structural transformations, tariff impacts, segmentation-specific considerations, regional nuances, competitive positioning, and practical recommendations for leaders seeking sustained advantage.

How technological breakthroughs, regulatory tightening, and care setting evolution are jointly reshaping parenteral nutrition supply, safety, and clinical utilization paradigms

The parenteral nutrition landscape is undergoing transformative shifts driven by converging forces in clinical demand, regulatory emphasis on sterility and safety, and advancements in compounding and delivery technologies. First, care continuity and the rise of outpatient and home-based therapies have pushed manufacturers and providers to reconfigure product portfolios toward stability, ease of administration, and compatibility with remote monitoring. This evolution aligns with an intensified focus on patient-centered care pathways and the need to reduce hospital lengths of stay.

Second, technology is redefining how parenteral nutrition is formulated and dispensed. Innovations in multi-chamber bag design, lipid emulsions, and additive compatibility reduce preparation time and contamination risk, while automated compounding systems and closed-system transfer devices improve reproducibility and safety. Meanwhile, digital tools for prescription management, electronic health record integration, and remote adherence monitoring facilitate tighter clinical oversight and optimization of nutrient delivery.

Third, regulatory and quality assurance frameworks have tightened, prompting providers to enhance aseptic processing, validate compounding environments, and adopt standardized protocols. These measures increase compliance costs but systematically lower risk, fostering trust among clinicians and payers. Finally, supply-chain resilience has emerged as a strategic priority, prompting firms to diversify sourcing, localize manufacturing where feasible, and invest in inventory visibility solutions. Collectively, these shifts compel industry participants to pursue operational agility, prioritize partnerships across the care continuum, and invest in product and service differentiation to meet evolving clinical and commercial expectations.

Evaluating the multifaceted operational, sourcing, and strategic consequences that new tariff policies impose on parenteral nutrition supply chains and commercial models

The introduction of new tariff measures by the United States in 2025 has introduced a distinct set of pressures that reverberate across procurement, manufacturing decisions, and pricing strategies within the parenteral nutrition domain. Tariffs on key imported inputs and finished products elevate landed costs for manufacturers and compounding pharmacies that depend on global supply networks, creating incentives to reassess sourcing footprints and vendor relationships. In response, many stakeholders will increase scrutiny of supplier contracts, favor nearshoring where quality and regulatory compliance permit, and accelerate supplier qualification to mitigate exposure to trade volatility.

At the operational level, higher import costs translate into cost containment initiatives across manufacturing and distribution. Companies may prioritize process efficiency programs, renegotiate distribution agreements, and optimize raw material utilization to preserve margins without compromising clinical performance. Payers and health systems, observing cost pressures, will intensify procurement negotiations and may favor products or service bundles that demonstrate clear value in reducing adverse events, readmissions, or total cost of care. Consequently, manufacturers must articulate product differentiation beyond unit price, emphasizing safety, stability, and clinical outcomes.

Moreover, tariffs catalyze innovation in domestic manufacturing capabilities. Investments in local aseptic fill-finish capacity, validated compounding services, and regional distribution hubs reduce dependence on cross-border shipments and shorten lead times. However, these investments carry capital and regulatory burdens that favor larger firms or partnerships between manufacturers and health systems. As a transitionary effect, smaller suppliers and niche producers could face competitive pressure unless they secure long-term contracts or specialization strategies.

Finally, the cumulative effect of tariffs interacts with existing regulatory and reimbursement dynamics, influencing strategic choices around portfolio composition, pricing models, and commercial engagement. Forward-looking organizations will likely adopt a multifaceted response that blends supply-chain diversification, operational efficiency, and closer clinical collaboration to preserve access and maintain high standards of patient care.

In-depth segmentation insights revealing how product type, composition, care setting, clinical application, delivery modality, and administration route drive differentiated strategic priorities

Segment-specific dynamics reveal differentiated opportunities and risks across product types, compositions, end-user segments, applications, delivery modes, and routes of administration. Within product type, peripheral parenteral nutrition supports shorter-term or less intensive needs and aligns with outpatient and homecare strategies, while total parenteral nutrition addresses complex clinical cases requiring comprehensive nutrient delivery and remains central to inpatient critical care and oncology applications. These contrasts shape demand patterns, inventory management practices, and compounding requirements across providers.

Compositionally, amino acid solutions, carbohydrate solutions, electrolyte solutions, lipid emulsions, and vitamin and trace element solutions each carry unique formulation, stability, and compatibility considerations. Amino acid profiles and lipid emulsion characteristics, for example, influence metabolic outcomes and tolerability, prompting clinicians to select formulations based on patient-specific needs. Compatibility concerns among electrolytes and additives drive protocols for sequencing, admixture, and monitoring, which in turn affect compounding workflows and product design priorities.

End-user dynamics vary markedly among clinics, homecare providers, and hospitals. Hospitals concentrate high-acuity care and require robust bulk compounding and closed-system supply logistics, whereas homecare demands portability, user-friendly packaging, and clear caregiver instructions to support long-term outpatient nutrition. Clinics often occupy an intermediate space, emphasizing efficient on-site compounding and rapid turnaround for short-duration therapies.

Application-driven differentiation is pronounced in critical care, oncology nutrition, and surgical nutrition. Critical care places premium value on sterility, rapid availability, and formulations tailored to metabolic stress. Oncology nutrition necessitates attention to immunocompromised status, electrolyte balance, and long-term tolerability, while surgical nutrition focuses on perioperative optimization and recovery metrics. These application nuances inform clinical protocols, reimbursement conversations, and product labeling.

Delivery mode segmentation between custom and pre-mixed options shapes manufacturing and service models. Custom solutions-produced via on-site compounding or outsourced compounding-offer individualized formulations but require stringent quality systems and validation processes. Pre-mixed products, supplied as multi-chamber bags or single-chamber bags, provide convenience and reduced preparation time, thereby lowering contamination risk and simplifying logistics. Finally, route of administration distinctions between central line and peripheral line approaches dictate catheter-related safety protocols, formulation osmolarity constraints, and device compatibility, all of which influence prescribing behavior and product development priorities.

Regional nuances in clinical practice, regulatory rigor, and manufacturing capacity that determine differentiated pathways for commercialization and supply resilience

Regional contexts shape clinical practice patterns, regulatory landscapes, and supply-chain architectures across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct commercial and operational implications. In the Americas, health systems demonstrate strong integration between acute care networks and homecare providers, creating demand for both hospital-grade TPN solutions and home-compatible peripheral options. Regulatory frameworks emphasize pharmacovigilance and sterile compounding standards, while reimbursement mechanisms increasingly reward outcomes that reduce hospital stay and readmission, thereby incentivizing product and service packages that support safe outpatient transition.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and divergent healthcare infrastructure create variable adoption trajectories. Western European markets prioritize stringent aseptic processing standards and advanced compounding technologies, reflecting high expectations for quality and safety. Meanwhile, parts of the Middle East and Africa focus on expanding basic access and building capacity for hospital-based parenteral nutrition, often relying on regional distribution partnerships and targeted training programs to bolster clinical competency.

Asia-Pacific presents a dynamic mix of rapid clinical adoption and local manufacturing expansion. Several countries in the region are investing in domestic sterile manufacturing and compounding services to reduce reliance on imports and improve supply continuity. Concurrently, the region's aging populations and increasing prevalence of chronic diseases drive rising use of parenteral nutrition in both hospital and home settings. Across these geographies, regional regulatory harmonization efforts and investments in cold chain and logistic infrastructure will determine the speed and scale of product diffusion.

Taken together, regional differences necessitate tailored market entry and commercialization strategies that consider regulatory compliance, distribution networks, healthcare delivery models, and local clinical practice. Strategic alignment with regional stakeholders and investment in education and quality assurance are pivotal to gaining clinician trust and establishing long-term presence.

Competitive positioning driven by proven aseptic manufacturing, product usability, supply-chain resilience, and clinical partnership initiatives that shape long-term adoption

Competitive dynamics within parenteral nutrition revolve around capabilities in formulation science, aseptic manufacturing, distribution breadth, and clinical engagement. Leading companies emphasize validated compounding platforms, robust quality systems, and investments in closed-system technologies to minimize contamination risk and demonstrate compliance with evolving sterile processing standards. Strategic collaborations between manufacturers and health systems or third-party compounding providers have become a common pathway to scale distribution while maintaining clinical oversight.

Product differentiation increasingly centers on stability profiles, ease of administration, and integration with clinical workflows. Companies that invest in multi-chamber bag innovations, compatibility testing, and patient-centric packaging gain traction in outpatient and homecare channels. Simultaneously, firms that support digital prescribing and adherence tools enhance clinical decision-making and create measurable value propositions for payers and providers. In an environment of cost pressures and tariff-induced headwinds, organizations that can document reductions in preparation time, contamination events, or hospital resource utilization unlock stronger procurement conversations.

Beyond product attributes, market participants that demonstrate supply-chain transparency and robust risk management earn trust among large health systems. Investments in regional manufacturing, redundant sourcing, and temperature-controlled logistics reduce exposure to trade disruptions and support just-in-time inventory models. Finally, companies that pair commercial offerings with clinician education, training programs for aseptic technique, and outcomes tracking deepen stakeholder relationships and position themselves as partners in quality improvement rather than mere suppliers.

Actionable strategic measures for leaders to reinforce quality, diversify supply chains, expand product convenience, and deepen clinical partnerships for sustainable growth

Industry leaders should pursue a coherent set of actions to strengthen resilience, differentiate offerings, and align commercial models with evolving clinical priorities. First, prioritize investments in quality systems and validated compounding infrastructure to ensure consistent sterility and regulatory compliance. This foundational step reduces clinical risk and positions organizations to scale services across hospital and outpatient settings. Second, pursue supply-chain diversification and selective nearshoring of critical components to mitigate tariff exposure and shorten lead times. Strategic supplier partnerships and regional manufacturing collaborations will smooth transitions and preserve continuity of care.

Third, accelerate development of pre-mixed and multi-chamber formats that simplify administration and reduce preparation-related contamination. Simultaneously, maintain a custom compounding capability to meet complex clinical needs, supported by rigorous validation and remote oversight where appropriate. Fourth, integrate digital tools that streamline prescribing, automate compatibility checks, and support adherence monitoring; these capabilities improve clinician efficiency and create measurable evidence for payers. Fifth, deepen clinical engagement through education programs, outcomes partnerships, and shared data initiatives that demonstrate the real-world impact of products and services on patient recovery and resource utilization.

Finally, adopt flexible commercial models that blend product supply with professional services such as compounding support, training, and outcomes analytics. Such bundled approaches will resonate with health systems seeking to contain costs while enhancing patient safety and continuity of care. Leaders that implement these recommendations will be better positioned to navigate regulatory change, tariff-related cost pressures, and shifting care delivery trends.

A rigorous mixed-methods research approach combining expert interviews, policy review, and scenario analysis to generate actionable clinical and commercial insights

The research underpinning this executive analysis employed a structured, multi-source methodology designed to capture clinical, regulatory, commercial, and operational dimensions of parenteral nutrition. Primary research included structured interviews with clinical leaders, pharmacy directors, compounding specialists, and procurement executives to understand decision criteria, pain points, and adoption drivers. These qualitative insights were triangulated with regulatory documentation, compounding standards, and published clinical literature to ensure alignment with prevailing practice and safety expectations.

Secondary sources informed contextual understanding of manufacturing technologies, distribution logistics, and recent policy shifts affecting trade and reimbursement. The analytic approach prioritized thematic synthesis over numerical extrapolation, focusing on causal relationships, operational implications, and strategic response options. Where appropriate, scenario analysis explored plausible trajectories for supply-chain adaptation, technology adoption, and care-setting migration, emphasizing pragmatic decision levers rather than speculative forecasting.

Throughout the research process, methodological rigor was preserved by validating findings with subject-matter experts and cross-referencing claims against multiple independent sources. Limitations include variability in regional data availability and the evolving nature of tariff and regulatory environments, which require readers to consider local context when applying insights. Nevertheless, the methodology yields a robust framework for actionable decision-making grounded in current clinical practice and industry realities.

A forward-looking synthesis that underscores the imperative to align quality, supply resilience, and clinical partnership to secure long-term leadership in parenteral nutrition

In conclusion, parenteral nutrition stands at the intersection of clinical necessity and operational complexity. The field's future will be shaped by the interplay of safer compounding technologies, regulatory expectations for aseptic practice, care-delivery shifts toward home and outpatient models, and the strategic responses organizations adopt to tariff-related disruptions. Stakeholders that invest in quality systems, diversify sourcing, and deliver clinician-centered products and services will be best positioned to sustain access and drive improved patient outcomes.

Moreover, organizations that pair product innovation with digital tools and clinical education can create differentiated value propositions that resonate with payers and health systems focused on reducing adverse events and length of stay. As the landscape continues to evolve, pragmatic, partnership-driven approaches that align commercial incentives with clinical goals will determine which companies capture long-term trust and adoption. Decision-makers should act now to align capabilities with emerging requirements, thereby ensuring both regulatory resilience and competitive advantage in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Parenteral Nutrition Market, by Product Type

  • 8.1. Peripheral Parenteral Nutrition
  • 8.2. Total Parenteral Nutrition

9. Parenteral Nutrition Market, by Composition

  • 9.1. Amino Acid Solution
  • 9.2. Carbohydrate Solution
  • 9.3. Electrolyte Solution
  • 9.4. Lipid Emulsion
  • 9.5. Vitamin And Trace Element Solutions

10. Parenteral Nutrition Market, by Route Of Administration

  • 10.1. Central Line
  • 10.2. Peripheral Line

11. Parenteral Nutrition Market, by Delivery Mode

  • 11.1. Custom
    • 11.1.1. On Site Compounding
    • 11.1.2. Outsourced Compounding
  • 11.2. Pre Mixed
    • 11.2.1. Multi Chamber Bags
    • 11.2.2. Single Chamber Bags

12. Parenteral Nutrition Market, by Application

  • 12.1. Critical Care
  • 12.2. Oncology Nutrition
  • 12.3. Surgical Nutrition

13. Parenteral Nutrition Market, by End User

  • 13.1. Clinics
  • 13.2. Homecare
  • 13.3. Hospitals

14. Parenteral Nutrition Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Parenteral Nutrition Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Parenteral Nutrition Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Parenteral Nutrition Market

18. China Parenteral Nutrition Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Aculife Healthcare
  • 19.7. Ajinomoto Co. Inc.
  • 19.8. Amanta Healthcare
  • 19.9. B. Braun Melsungen AG
  • 19.10. Baxter International Inc.
  • 19.11. Fresenius Kabi AG
  • 19.12. Grifols S.A.
  • 19.13. ICU Medical, Inc.
  • 19.14. JW Pharmaceutical Corporation
  • 19.15. Meiji Holdings Co., Ltd.
  • 19.16. Option Care Health Inc.
  • 19.17. Otsuka Pharmaceutical Co.
  • 19.18. Pfizer Inc.
  • 19.19. Sichuan Kelun Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PARENTERAL NUTRITION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PARENTERAL NUTRITION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PARENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PERIPHERAL PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PERIPHERAL PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PERIPHERAL PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY AMINO ACID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY AMINO ACID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY AMINO ACID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CARBOHYDRATE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CARBOHYDRATE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CARBOHYDRATE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ELECTROLYTE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ELECTROLYTE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ELECTROLYTE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY LIPID EMULSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY LIPID EMULSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY LIPID EMULSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY VITAMIN AND TRACE ELEMENT SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY VITAMIN AND TRACE ELEMENT SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY VITAMIN AND TRACE ELEMENT SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CENTRAL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PERIPHERAL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PERIPHERAL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PERIPHERAL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ON SITE COMPOUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ON SITE COMPOUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ON SITE COMPOUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY OUTSOURCED COMPOUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY OUTSOURCED COMPOUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY OUTSOURCED COMPOUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY MULTI CHAMBER BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY MULTI CHAMBER BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY MULTI CHAMBER BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY SINGLE CHAMBER BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY SINGLE CHAMBER BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY SINGLE CHAMBER BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ONCOLOGY NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ONCOLOGY NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY ONCOLOGY NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY SURGICAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY SURGICAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY SURGICAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 189. G7 PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 190. G7 PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 198. NATO PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 199. NATO PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA PARENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA PARENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA PARENTERAL NUTRITION MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA PARENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA PARENTERAL NUTRITION MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA PARENTERAL NUTRITION MARKET SIZE, BY CUSTOM, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA PARENTERAL NUTRITION MARKET SIZE, BY PRE MIXED, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PARENTERAL NUTRITION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PARENTERAL NUTRITION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)